This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Phibro (PAHC) Q3 Earnings Lag Estimates, 2022 Revenue View Up
by Zacks Equity Research
In Q3, Phirbo (PAHC) reports growth in the Animal Health business on higher sales of processing aids, which are used to improve production efficiency in the ethanol fermentation industry.
Phibro Animal Health (PAHC) Q3 Earnings Miss Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of -8.33% and 3.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Phibro (PAHC) Stock For Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC) owing to the robust performances by its Animal Health and Mineral Health segments.
The Zacks Analyst Blog Highlights Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group
by Zacks Equity Research
Becton Dickinson, Phibro Animal Health, McKesson, and UnitedHealth Group are part of top Analyst Blog.
Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022
by Riya Anand
Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.
Is Phibro Animal Health (PAHC) a Good Stock for Value Investors?
by Zacks Equity Research
Let's see if Phibro Animal Health Corporation (PAHC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Add Phibro (PAHC) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) booming vaccine business and diverse product lines.
Why Is Phibro (PAHC) Up 2.2% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro Animal Health (PAHC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Innoviva (INVA) and Phibro Animal Health (PAHC) have performed compared to their sector so far this year.
Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
by Zacks Equity Research
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
Land on 5 Winning Stocks With the Overlooked Rising P/E Trick
by Sanghamitra Saha
Stocks with rising P/E often proves to be an intriguing investing idea.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro (PAHC) Q2 Earnings Surpass Estimates, 2022 View Up
by Zacks Equity Research
Phibro (PAHC) reports better-than-expected earnings for the fiscal second quarter. Robust performances by the Animal Health and Mineral Health segments drove the top line.
Here's Why You Should Retain Phibro (PAHC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.
Phirbo's (PAHC) Rising Costs, Currency Headwind Ail Growth
by Zacks Equity Research
Though Phirbo (PAHC) has raised prices on selective products, these increases do not fully compensate for the higher cost of freight and labor materials.
Phibro (PAHC) Down 12.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic
by Zacks Equity Research
Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.
Phirbo (PAHC) Q1 Earnings Lag Estimates, Revenue View Up
by Zacks Equity Research
Phirbo's (PAHC) year-over-year increase in Q1 sales is primarily due to stronger international demand for poultry and cattle products and more robust growth in the nutritional specialties and vaccine product lines.
Petco (WOOF) Down 26% This Year So Far: What Should You Do?
by Zacks Equity Research
Petco (WOOF) with its omni-channel distribution and a well-diversified product offering is strongly placed in the pet care industry, which is growing rapidly.
Why Is Phibro (PAHC) Down 6.1% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.